People with coronavirus are at risk of blood clots and strokes

Recent data from the Netherlands and France suggest that of the patients with coronavirus who are admitted to intensive care units (ICU), 30-70% develop blood clots in the deep veins of the legs, or in the lungs.

Around one in four coronavirus patients admitted to ICU will develop a pulmonary embolism.

These rates are much higher than we would usually see in patients requiring admission to ICU for reasons other than COVID-19.

Patients who present to hospital with COVID-19 are also more likely to have a stroke when compared with the general population.

Typically, the chance of having a stroke is associated with increasing age, as well as other risk factors such as high blood pressure, elevated cholesterol levels, or smoking.

However, higher rates of strokes in patients with COVID-19 is somewhat unusual because it also seems to be happening in people under 50 years of age, with no other risk factors for stroke.

COVID-19 also appears to be associated with blood clots in the tiny blood vessels that are important for the transfer of oxygen in organs. Autopsy reports have shown elements of SARS-CoV-2, the virus causing COVID-19, in cells lining these small blood vessels in the lungs, kidney, and gut.

This may result in tiny blood clots in these small blood vessels that disturb normal blood flow and the ability of the blood to deliver oxygen to these organs.

Importantly, these small blood clots could reduce normal lung function. If these small blood clots reach the lungs it may prevent oxygen getting into the blood as efficiently as normal. This may explain why patients with severe COVID-19 can have very low oxygen levels.

When patients are admitted to hospital, for coronavirus or any other condition that leaves them bed-bound, it is common practice to administer low-dose blood thinners to prevent the development of blood clots.

However, given that patients with COVID-19 seem to be at a higher risk of developing blood clots, it’s currently being debated whether higher doses of blood thinners are required to prevent these clotting complications.

Trials are underway to attempt to answer this important question.

Diagnosing these blood clots in patients with COVID-19 can also be particularly challenging.

Firstly, the symptoms of a worsening lung infection associated with the virus can be indistinguishable from the symptoms of a pulmonary embolism.

Another challenge in COVID-19 is that the virus can impact laboratory tests which may also be used to diagnose venous blood clots.

A good example of this is a test called D-dimer, which is a measure of clotting in the body. Normally, this test would be higher in almost everyone with new venous blood clots. However, people with severe COVID-19 infection can also have an elevated D-dimer simply due to the severe infection.

In some patients, this means that the test is no longer helpful to diagnose blood clots.

One theory is that the increased rate of blood clots in COVID-19 is simply a reflection of being particularly unwell and immobile.

However, the current data suggest the risk of blood clots is significantly greater in patients with COVID-19 than what is usually see in patients admitted to hospital and ICUs.

Another potential explanation is that the virus is directly impacting on the cells lining our blood vessels. When the body fights an infection, the immune system becomes activated to try and kill the invader, and research shows an activated immune system can cause blood clots.

In severe COVID-19, the immune system appears to go into overdrive. This could lead to the unchecked activation of cells that typically stop blood clotting.

Another possibility is that the virus triggers blood clotting to provide it with a survival advantage.

The SARS virus, another member of the coronavirus family, can be further “activated” by a blood clotting protein, enabling the virus to more efficiently invade cells.

However, whether this is the case with COVID-19 remains to be investigated.

Intriguingly, preliminary research suggests that a commonly used blood thinner, heparin, may have antiviral effects by binding to SARS-CoV-2 and inhibiting a key protein the virus uses to latch onto cells.

What we know for sure is that blood-clotting complications are rapidly emerging as a significant threat from COVID-19. In this area, we still have much to learn about the virus, how it affects blood clotting, and the best options for prevention and treatment of these blood clots.